कंपनी का अवलोकन
Pelthos Therapeutics Inc. operates as a bio-pharmaceutical entity dedicated to developing and commercializing therapeutic products aimed at alleviating unmet treatment burdens for patients. The company functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, which implies a focus on innovative drug discovery and specialized medical treatments. As of the latest reporting period, the firm maintains a market capitalization of $75.47M, generates annual revenue of $16.80M, and employs a workforce of 92 individuals. These financial figures indicate that Pelthos Therapeutics is a mid-cap biotechnology company with a relatively small operational footprint, reflecting its stage of development where capital is heavily directed toward product commercialization rather than mature cash flow generation. The specific product portfolio includes ZELSUVMI for treating molluscum contagiosum in adults and children one year of age and older, as well as XEPI (ozenoxacin) cream, demonstrating a targeted approach to niche therapeutic areas.
वित्तीय स्वास्थ्य
The company reported a revenue of $16.80M over the trailing twelve months, yet this figure contrasts sharply with a net income of $-43,319,000 and an EBITDA of $-29,123,000. The significant gap between revenue and net income reveals a highly expansive cost structure typical of early-stage biotechnology firms, where research, development, and commercialization expenses substantially outweigh operational revenues. Free cash flow stands at $-24,652,500, indicating that the company is currently burning cash to fund its operations and growth initiatives rather than generating liquidity from its core business activities. The gross margin is reported at 68.9%, suggesting that the cost of goods sold is managed efficiently relative to sales, while the operating margin of -127.8% and profit margin of -257.9% highlight severe operational losses that erode profitability before considering non-operating factors. On the balance sheet, total cash holdings of $17.97M are insufficient to cover total debt obligations of $34.83M, resulting in a debt-to-equity ratio of 89.58 which signifies a highly leveraged financial position dependent on external financing. The current ratio of 2.06 suggests that the company possesses adequate short-term liquidity to cover its immediate obligations, though the high leverage remains a critical risk factor. Furthermore, the return on equity is -239.6% and the return on assets is -29.8%, metrics that indicate management is currently unable to generate positive returns on the capital invested by shareholders or utilized in assets.
मूल्यांकन आकलन
Valuation metrics present a complex picture due to the company's lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -52.30. The negative forward P/E implies that analysts or market participants expect earnings to remain negative in the near future or that the company is not currently profitable enough to support a standard earnings-based valuation multiple. The price-to-book ratio is 1.87, indicating that the stock trades at a premium of 87% above its book value, which may reflect market optimism regarding the potential of its therapeutic pipeline despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 4.49 and an EV/EBITDA of -3.17 suggest that the market is pricing the company based on its sales potential and asset base rather than current earnings power. The 52-week high is $54.29 and the 52-week low is $9.00, providing a wide trading range that underscores the high volatility inherent in small-cap biotechnology stocks. The beta value of 3.94 indicates that the stock price is highly sensitive to market movements, fluctuating nearly four times as much as the broader market index.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's status as a pre-profitability entity where historical growth rates may not be available or meaningful in the traditional sense. Without positive earnings, the concept of dividend yield and payout ratio does not apply in a conventional manner, as the dividend yield is N/A and the payout ratio is 0.0%. Consequently, the company does not distribute cash to shareholders but instead retains all available capital to reinvest into research, development, and commercialization efforts to advance its therapeutic products. The overall growth and income profile is characterized by significant cash consumption rather than income generation, with the firm relying entirely on capital markets or existing cash reserves to fund its operations until profitability is achieved.